BackFulcrum Therapeutics Overview
Fulcrum Therapeutics Inc

Fulcrum Therapeutics Target Price

Where could FULC trade next? Consensus target price: $3.6.

Get informed when a big investor buys or sells

+ Follow

Share Price

$3.71

Average Target Price

$3.603% downside

5 analysts in the last 4 months

High: $4 | Low: $3

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-06-02H.C. WainwrightAndrew Fein$319.1% downsideOpen
2026-06-02Jefferies$47.8% upsideOpen
2026-06-02Leerink Partners$47.8% upsideOpen
2026-06-02Truist FinancialGregory Renza$47.8% upsideOpen
2026-06-02Piper Sandler$319.1% downsideOpen
2026-02-24Truist FinancialGregory Renza$17358.2% upsideOpen
2025-12-11Truist Financial$18385.2% upsideOpen
2025-12-08Stifel Nicolaus$25573.9% upsideOpen
2025-12-08Cantor FitzgeraldKristen Kluska$24546.9% upsideOpen
2025-12-08RBC Capital$10169.5% upsideOpen
2025-12-08Piper Sandler$23519.9% upsideOpen
2025-12-08H.C. Wainwright$25573.9% upsideOpen
2025-11-24Truist Financial$14277.4% upsideOpen
2025-11-24H.C. WainwrightAndrew Fein$18385.2% upsideOpen
2025-10-30Piper Sandler$16331.3% upsideOpen
2025-10-21Leerink Partners$20439.1% upsideOpen
2025-07-29H.C. Wainwright$12223.5% upsideOpen
2025-05-29Piper SandlerEdward Tenthoff$9142.6% upsideOpen
2025-05-23Leerink PartnersJoseph Schwartz$12223.5% upsideOpen
2024-09-13H.C. WainwrightAndrew Fein$47.8% upsideOpen
2024-09-12RBC CapitalGregory Renza$47.8% upsideOpen
2024-09-12Stifel NicolausDae Gon Ha downgraded Fulcrum Therapeutics$319.1% downsideOpen
2024-09-12Bank of America SecuritiesTazeen Ahmad$246.1% downsideOpen
2024-09-09Bank of America SecuritiesTazeen Ahmad$10169.5% upsideOpen
2024-09-03RBC CapitalGregory Renza$15304.3% upsideOpen
2024-05-20Cantor FitzgeraldKristen Kluska$23519.9% upsideOpen
2024-05-13Goldman SachsCorinne Jenkins$15304.3% upsideOpen
2024-05-13Stifel NicolausDae Gon Ha$22493% upsideOpen
2024-03-13RBC CapitalGregory Renza$14277.4% upsideOpen
2022-11-15Goldman Sachs$11196.5% upsideOpen
2022-11-08Piper SandlerEdward Tenthoff$18385.2% upsideOpen

Fulcrum Therapeutics (FULC) FAQ

Fulcrum Therapeutics posts a target price of $3.6. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $3.6 for FULC means covering analysts, on average, see the stock 3.0% downside of $3.71 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for FULC's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Fulcrum Therapeutics's other metric pages and overview cover the third.

Judging Fulcrum Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $3.6 here, then scan peer and history charts to see if the gap is persistent.